Cargando…
Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activated Calcium Channel Inhibitor
To assess the safety of Auxora in patients with acute pancreatitis (AP), systemic inflammatory response syndrome (SIRS), and hypoxemia, and identify efficacy endpoints to prospectively test in future studies. METHODS: This phase 2, open-label, dose-response study randomized patients with AP, accompa...
Autores principales: | Bruen, Charles, Miller, Joseph, Wilburn, John, Mackey, Caleb, Bollen, Thomas L., Stauderman, Kenneth, Hebbar, Sudarshan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104014/ https://www.ncbi.nlm.nih.gov/pubmed/33939666 http://dx.doi.org/10.1097/MPA.0000000000001793 |
Ejemplares similares
-
Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial
por: Miller, Joseph, et al.
Publicado: (2020) -
Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial
por: Bruen, Charles, et al.
Publicado: (2022) -
Orai1 calcium channel inhibition prevents progression of chronic pancreatitis
por: Szabó, Viktória, et al.
Publicado: (2023) -
A Store-operated Calcium Channel in Drosophila S2 Cells
por: Yeromin, Andriy V., et al.
Publicado: (2004) -
Quantal calcium release and calcium entry in the pancreatic acinar cell.
por: Pandol, S. J., et al.
Publicado: (1992)